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The 2000 Hajj (March 15–18) was followed by an outbreak of Neisseria meningitidis W135 2a: P1.2,5 in
Europe. From March 18 to July 31, 2000, some 90 cases of meningococcal infection were reported from
nine countries, mostly the United Kingdom (UK) and France; 14 cases were fatal. Although most early
cases were in pilgrims, the outbreak spread to their contacts and then to those with no known pilgrim
contact. In France and the UK, the outbreak case-fatality rate was compared with the rate reported from
national surveillance. The risk of dying during this outbreak was higher in France and the UK, although
the difference was not statistically significant. Prophylaxis for all pilgrims and their household contacts
was offered in France; in the UK and other European countries, prophylaxis was recommended only for
close contacts. No difference in transmission rates following intervention was detected between France
and the UK.
he annual Islamic pilgrimage to Mecca, the Hajj, attracts
more than a million pilgrims from many countries world-
wide and has been associated with outbreaks of meningococ-
cal disease. The first reported international outbreak of this
disease following the Hajj, which was caused by Neisseria
meningitidis serogroup A, occurred in 1987 (1–3). That epi-
demic emphasized the potentially high risk of transmission of
N. meningitidis during the pilgrimage. Before this outbreak,
vaccination against N. meningitidis serogroup A was required
only for pilgrims from sub-Saharan countries to obtain a visa
for Saudi Arabia (4). After this outbreak, vaccination became
compulsory for all subsequent pilgrims. In 1992, another
group A outbreak occurred in Mecca during Umra and
Ramadan, but this outbreak was not known to have spread
beyond Saudi Arabia (4). Subsequently, the vaccination policy
was extended to all Umra visitors.
In March and April 2000, national reference centers (NRC)
for meningococci in several European countries detected a
sharp rise in isolates of N. meningitidis serogroup W135, sero-
type 2a subtype P1.2,5. This strain, rarely isolated in European
countries, belonged to the electrophoretic type 37 (ET-37)
clonal complex, which is known to cause hyperendemic dis-
ease activity (5). Cases of meningococcal disease caused by
serogroup W135 following the Hajj were also reported from
Saudi Arabia, the United States, and some countries in North
Africa, the Middle East, and Asia (6,7). 
In most European countries, according to national policies,
prophylaxis was recommended only for close contacts of
cases. In France, as soon as the outbreak was recognized
(April 8, 2000, week 14), the Ministry of Health recommended
a 2-day course of rifampicin for all pilgrims and their house-
hold contacts, with the objectives of preventing cases in pil-
grims’ households and limiting the spread of the outbreak
strain in the population.
We describe the epidemiology of the outbreak in Europe
and evaluate the impact of the French intervention. 
Methods
A confirmed case was defined as invasive disease caused
by N. meningitidis of serogroup W135 2a P1.2,5 or belonging
to the ET-37 complex. A probable case was defined as illness
in a pilgrim or a pilgrim contact, with either invasive disease
due to N. meningitidis serogroup W135 of unknown serotype
(identified by polymerase chain reaction [PCR] or detection of
specific antigens) or with a clinical diagnosis of invasive men-
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ingococcal infection without microbiologic confirmation.
Cases included were those with dates of hospital admission
from March 18, 2000, until July 31, 2000. 
Nonpilgrim case-patients were classified as 1) living in the
same household as a pilgrim during the 7 days before the date
of onset, 2) being in contact with a pilgrim but not living in the
same household during the 7 days before the date of onset, or
3) having no identified contact with a pilgrim. 
A questionnaire was sent by e-mail in April 2000 to the
National Surveillance Centers in Europe, and interviews of
cases were conducted by telephone or in person. For each case,
information was anonymously requested on demography, eth-
nicity, clinical symptoms, medical history, housing situation,
meningococcal vaccination history, contact with Hajj 2000 pil-
grims, and travel to Saudi Arabia. Results of the microbiologic
investigation were obtained from NRC. Additionally, the num-
ber of visas delivered for the Hajj 2000 was obtained from
Saudi embassies, and information was collected in France on
the observance of the specific prophylactic measures for pil-
grims and their household contacts.
As cases occurred predominantly in France and the UK,
only these two countries were considered in further analysis.
The case-fatality rate (CFR) observed in cases from France
was compared with the CFR of all N. meningitidis infections
reported to the national surveillance system in France during
1995–1999. The same comparison was performed for the UK.
The probability of dying from the outbreak strain was esti-
mated for France and the UK by using a logistic regression
model. In addition to the outcome (death), variables included
in the model were age and having an epidemic case versus a
national surveillance case. Consecutively, the age-adjusted rel-
ative risks (RR) of dying from the epidemic were estimated
from the odd ratios by the log link function. 
To evaluate the impact of the French control measures
implemented on April 8, we compared the number of cases in
France with those in the UK before and after April 8 for a) pil-
grim and household contacts, and b) out-of-household contacts
and those for whom no contact with a pilgrim was identified.
The ratio of cases in France after and before the intervention
was compared with the same ratio in the UK. An effective
intervention would be expected to result in a measure of
impact less than one, and vice versa. Confidence intervals
were determined by Poisson regression. The p-values were
estimated by Fisher’s exact test. 
The descriptive analysis was carried out with Epi Info
(Centers for Disease Control and Prevention, version 6.04c).
The logistic regression was performed with Stata version 6.0
(Stata Corporation, College Station, TX). Data on cases
reported during 1995–1999 were issued from the Public
Health Laboratory Service in the UK and from the Institut de
Veille Sanitaire in France.
Results
From March 18 to July 31, 2000, some 90 cases of sero-
group W135 meningococcal disease were ascertained from
nine European countries (the UK, France, the Netherlands,
Germany, Finland, Sweden, Belgium, Switzerland, and Nor-
way) (Figure 1). Questionnaires were fully completed for 80
cases (89%), and partly completed for 10 cases. Eighty-four
isolates (93%) were confirmed as N. meningitidis serogroup
W135 serotype 2a subtype P1.2,5. Six probable cases were
diagnosed by soluble antigen detection (one case) or PCR (five
cases). Microbiologic examination of bacterial isolates was
described elsewhere (5).
The Hajj 2000 was held March 15–18, 2000 (week 11).
The peak of the outbreak was rapidly reached in week 14, two
weeks after the first return of pilgrims from Mecca. Since that
time, the number of cases regularly decreased (Figure 2a). Of
90 cases, 45 (50%) occurred during the first 4 weeks after the
first return of pilgrims. In the UK, the first reported cases
occurred within 1 week after the Hajj and increased rapidly to
a peak of 12 cases in week 14 (Figure 2b). In France, the out-
break started and peaked in week 13 (Figure 2c). For the other
countries, cases occurred sporadically during the 4 months
after the Hajj. 
Twelve cases (13%) were in pilgrims (all vaccinated with
vaccine against meningitis A and C before traveling to
Mecca), 31 (34%) in household contacts of a pilgrim, and 21
(23%) in contacts outside the household; for 26 cases (29%),
no pilgrim contact was identified. 
A total of 19,749 pilgrims from the UK and 19,100 from
France participated in the Hajj 2000. Eight cases of meningo-
coccal disease occurred in the UK and four in France, giving
incidence rates in the pilgrim population of 41 and 21/100,000,
respectively. No cases occurred in pilgrims from other
Figure 1. Cases of W135 meningococcal disease reported per country
in Europe after Hajj 2000, March 18–July 30, 2000.Emerging Infectious Diseases  •  Vol. 8, No. 8, August 2002 763
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countries, although Germany had 18,000 pilgrims and the
Netherlands had 4,500 pilgrims. For Finland, Sweden, Bel-
gium, Switzerland, and Norway, no data were available on
visas delivered. 
Pilgrims were affected first (all cases in pilgrims were
reported in the 4 weeks after the Hajj): the peak of cases
occurred in week 13, household contacts cases peaked in week
14, out-of-household contact cases peaked in week 16, and
cases with unknown or no identified contact with a pilgrim
peaked in week 19 (Figure 3). 
Forty-seven (54%) of the 87 patients whose sex was
known were female. Fifty-one (65%) of the 78 nonpilgrim
patients were <5 years of age. The median age of the pilgrim
patients was 51 years; for nonpilgrims, it was 2 years.
Figure 2. Cases of W135 invasive meningococcal disease by week of
hospital admission, March–July 2000: a. Europe (90 cases), b. the
United Kingdom (42 cases), and c. France (24 cases).
Figure 3. Cases of W135 invasive meningococcal disease, by week of
hospital admission and type of contact, Europe, March–July 2000.RESEARCH
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Information on clinical features was available for 69 cases,
including meningitis (30 cases), septicemia (23 cases), or both
(16 cases). Arthritis (six cases), osteomyelitis (one), and pneu-
monia (one) were also reported from patients with septicemia.
Purpura fulminans was reported in 12 cases. Thirteen patients
had underlying long-term diseases, but none had preexisting
immunodeficiency. In the UK, 75% of patients were of Indian
ethnicity; in France, the majority (74%) were North African. 
Fourteen patients died (CFR 15.6%, 14/90) (Table 1). In
France, 4 (16.7%) of 24 case-patients died, compared with 152
(10.3%) of 1,481) observed for meningococcal disease due to
all serogroups of N. meningitidis in France from 1995 to 1999.
The age-adjusted RR of dying during the outbreak was 1.26,
(95% CI [0.52; 3.06], p=0.63). In the UK, 8 (19.0%) of 42
patients died, compared with 862 (8.3%) of 10,448 observed
for meningococcal disease due to all serogroups of N. menin-
gitidis in the UK during1995–1999. The age-adjusted RR was
1.99 (confidence interval 1.02; 2.74, p=0.06). There was no
evidence that the RR in France differed from the RR in the UK
(p=0.55). 
The median length of stay in Saudi Arabia for pilgrim
case-patients was 21 days (range 14–40). The median interval
between the beginning of the Hajj and the date of onset of dis-
ease was 16 days (range 11–29); the median interval between
return from the pilgrimage and the onset of disease was 2 days
(range 0–8). Among cases with pilgrim contact, the median
interval between return of the pilgrim from Mecca and onset of
disease was 8 days for household contacts and 6.5 days for
out-of-household contacts (p=0.58). Further characteristics of
pilgrim cases and cases by type of contact with a pilgrim are
shown in Table 2.
Regarding the assessment of the French recommendations,
the comparison between France and the UK of the ratio of
cases after and before interventions were put in place was 2.43
for pilgrims and their household contacts. This result of >1
yields no evidence that the French measures had a positive
impact in preventing cases in pilgrims and their household
contacts (p=0.27) (Table 3). The ratio among out-of-household
and no known contacts was 0.56, indicating a possible positive
impact of the measures in limiting the spread of the outbreak
strain, although the result was not statistically significant
(p=0.62).
Discussion
This report is the first description of a European meningitis
outbreak involving nine countries. An international coordina-
tion group was set up within 2 weeks after the outbreak was
recognized in Europe, followed by an early warning alert to all
the European countries. This facilitated information sharing,
standardization of the case definition, and implementation of a
standardized questionnaire for the investigation. The willing-
ness of participant countries led to a satisfactory completion
rate for reports, allowing a precise description of the outbreak
throughout Europe. However, case ascertainment may have
varied in different countries since some countries identified
cases through microbiologic findings only and some through
clinical as well as microbiologic findings. 
In 1987, an outbreak of meningococcal disease linked to
the Hajj was described in several European countries, but the
description was limited to pilgrim cases and a few secondary
Table 1. Cases of W135 meningococcal disease reported from nine 
European countries following Hajj, 2000
UK (no., 
% ; n=42)
France (no., 
% ; n=24)
All other coun-
tries (no., % ; 
n=24) a
Total (no., 
% ; n=90)
Sex ratio (M/F) 0.6 0.7 1.7 0.9
Age distribution 
<1 year 6 (14) 3 (13) 5 (21) 14 (16)
1–4 14 (33) 7 (29) 14 (58) 35 (39)
5–9 6 (14) 2 (8) 0  8 (9)
10–19 0   2 (8) 1 (4) 3 (3)
20–49 7 (17) 3 (13) 1 (4) 10 (11)
50–65 5 (12) 4 (17) 0  10 (11)
>65 4 (10) 3 (13) 1 (4) 8 (9)
Unknown 0 0 2 2
No. of deaths
<1 year 0 0 0 0
1–4 1 1 2 4
5–9 1 0 0 1
10–19 0 0 0 0
20–49 3 1 0 4
50-64 1 1 0 2
>65 2 1 0 3
CFR (overall) 19.0% 16.7% 8.3% 15.6%
aThe Netherlands, Germany, Finland, Sweden, Belgium, Norway, and Switzerland.
CFR, case-fatality rate.
UK, United Kingdom.
Table 2. Characteristics of pilgrim and contact cases in Europe follow-
ing the Hajj, 2000
Pilgrims
Household 
contacts 
Outside-of- 
household 
contacts
No identified 
contact 
No. of cases 12 31 21 26
Mean age (yrs) 50.0 16.0 6.9 25.8
Sex ratio (M/F) 4/8 13/18 13/8 10/13a
Median no. of bed-
rooms in household
3.0 2.5 2.5 2.0
Median no. of 
rooms in household
6.0 5.0 5.5 4.0
CFR 5/12 
(41.7%)
3/31 
(9.7%)
1/18 
(5.6%)
5/21 
(23.8%)
a Sex not known for three cases.
CFR, case-fatality rate.Emerging Infectious Diseases  •  Vol. 8, No. 8, August 2002 765
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cases (1–3). In the Hajj 2000 outbreak, the added value of
molecular biological investigation, together with the epidemi-
ologic investigation, allowed us to describe a W135 clonal
outbreak and the diffusion of this strain from pilgrims to the
general population (5). In Sweden, N. meningitidis W135 of
the same serotype and subtype has been documented since
1979, but pulsed-field gel electrophoresis and the sulfadiazine
resistance of the W135 isolates indicate that the outbreak was
probably due to a new strain of W135 meningococci (8). 
After its description in 1968 and during the 1970s, N. men-
ingitidis W135 was considered a minor serogroup, of little
clinical importance (9). Only in the early 1980s was this
organism described as a fully pathogenic strain, as an impor-
tant new cause of disease in Europe and the United States and
as an emerging cause of meningococcal disease in Africa
(10,11). During the 1990s, N. meningitidis W135 represented
2.6% to 4% of all reported N. meningitidis in the UK, France,
and the United States (12–14). The first two cases of meningo-
coccal disease in pilgrims due to W135 associated with the
Hajj were described in 1993 in Saudi Arabia in an Indonesian
and an American pilgrim (15).
From 1998 to March 2000, fewer than two cases of the
W135 2a:P1-5,2 strain were reported yearly in England and
Wales (Kaczmarski EB, pers. comm.) and two cases per year
in France (Taha MK, pers. comm.). The outbreak strain
belonged to the ET-37 complex, which is mainly composed of
serogroup C (16). The ET-37 complex has caused hyperen-
demic disease activity and outbreaks worldwide. It causes dis-
ease in clusters and has a higher transmissibility than other
strains (5,17,18). 
Although the CFRs in cases from France and the UK were
high, the age-adjusted RRs of dying during the outbreak were
not significantly higher than those observed in the routine sur-
veillance of meningococcal disease due to all serogroup of N.
meningitidis in these two countries. Thus, the outbreak strain
appears to be of similar virulence to N. meningitidis sero-
groups that normally cause meningococcal disease in the UK
and France. CFRs have been shown to be linked with age and
to increase among very young and older people (19). The ini-
tially large number of cases in older people at the beginning of
the outbreak might explain this finding. 
Methods used to evaluate the impact of the specific control
measures implemented in France intended to take into account
differences in meningococcal disease incidence rates between
the two countries and potential differences in pilgrims’ initial
carriage of the outbreak strain at their return from Mecca.
Since the number of cases in each group (pilgrims, household,
out of household, and no identified contact with a pilgrim) was
low, the power of the test did not allow identification of the
difference of impact between them. Defining other groups
could not have allowed conclusions to be drawn, since the
number would have also been low. Information collected from
the only manufacturer of rifampicin in France indicated that
the total number of doses distributed to pharmacies repre-
sented only half the doses needed to treat the target group
(approximately 100,000 persons living in pilgrims’ house-
holds), indicating that compliance with the recommendations
was low. In addition, all those who were provided treatment
may not have taken it effectively, although compliance would
not be expected to be a major problem with only 2 days of
medication. As of the end of March 2001 in France, no cases
were reported in persons who had taken rifampicin and no
strain of N. meningitidis W135 resistant to rifampicin had been
isolated at the NRC. For the prevention of cases among pil-
grims and household contacts, the <1 ratio between France and
the UK indicated that the measure had no impact in preventing
cases in pilgrims and pilgrims’ household in France. This
might be due to the delay of 2 weeks between the first return of
pilgrims and the release of the measure, an interval during
which transmission of the pathogenic strain occurred inside
the pilgrims’ households. 
The absence of significant impact of the measure to limit
the diffusion of the pathogenic strain to the out-of-household
contacts and persons with no contacts identified may be
Table 3. Number (and ratio) of cases in United Kingdom (UK) and France before and after a French Ministry of Health recommendationa 
UK (n=42) France (n=24)
Measure of impact 
(Ratio France / ratio UK)
No. of cases Ratio No. of cases Ratio
Before After After/before Before After After/before
Pilgrim cases (a) 8 0 3 1
Household contacts (b) 9 5 4 4
(a)+(b) 17 5 0.3 7 5 0.7 2.4 [0.5; 11.1]; p=0.27
Outside-of-household contacts (c) 2 4 2 5
No identified contact (d) 0 14 0 5
(c)+(d) 2 18 9 2 10 5 0.6 [0.1; 4.6]; p=0.62
All cases  19 23 1.2 9 15 1.7 1.4 [0.5; 3.8];p=0.61
aApril 8, 2000. Ratio is divided by the same ratio in the United Kingdom and its 95% confidence interval. RESEARCH
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explained either by the very small number of cases considered
or by potential misclassification. Cases in the general popula-
tion may also have been underestimated in comparison with
the likely high case ascertainment in pilgrims. However, such
underestimates are unlikely since virtually all invasive strains
of  N. meningitidis are sent to the reference laboratory in
France and the UK. However, data for cases of W135, 2a
P1.2,5 obtained from national reference laboratories in France
and the UK for September 2000–February 2001 indicated that
13 cases were reported in the UK and 9 in France, suggesting
that there was no long-lasting effect of the measure and that
immunity to the strain was probably increasing in the popula-
tion (20). In the UK, carriage studies showed that this strain
was still circulating within the Muslim community (Stuart JM,
pers. comm.). The results of the measures implemented in
France do not allow us to draw conclusions for use of mass
prophylaxis in the future, mainly because of the small number
of cases in our study. 
Following this outbreak, France and the UK, among other
countries, recommended quadrivalent vaccine for travelers to
the Hajj 2001 (21,22; pers. comm., Secrétariat du Conseil
Supérieur d'Hygiène Publique de France). Subsequent
quadrivalent vaccine coverage was estimated to be 47% and
65% in the UK and in France, respectively. Another outbreak
of meningococcal disease caused by N. meningitidis W135 2a
P1.2,5 occurred in Hajj pilgrims and their contacts in 2001;
most cases were from Saudi Arabia and the UK. During the
period March 28–June 29, 2001, 10 cases of meningococcal
disease due to W135 2a P1.2,5 were reported to the NRC in
France (0 deaths) and 25 in the UK (8 deaths) (23–25). Since
May 2001, quadrivalent vaccine is now a requirement for all
pilgrims to future Hajj pilgrimages (26). 
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